Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease

Inclusion Criteria: * Obese or overweight adult patients with congenital heart disease * BMI between 30 kg/m² and 40 kg/m² * Prior comprehensive non-pharmacological and non-surgical management of obesity, including a history of at least 12 months of intensive lifestyle intervention with a maximum weight reduction of less than 5% * Stable body weight within the three months preceding study enrollment (defined as weight fluctuations within 5%) * No prior pharmacological or surgical interventions for obesity * Euthyroid state * Eumenorrhea or oligomenorrhea * Ability to comprehend the study objectives and procedures * Willingness to provide informed consent and to comply with the study protocol, including the use of highly effective contraception during the study period, with signed consent and agreement provided in duplicate * Commitment to use highly reliable contraception and absence of plans for pregnancy within the 8 months following enrollment. Exclusion Criteria: * Down syndrome * Type 2 diabetes * Severe heart failure (NYHA IV), EF of systemic or subpulmonary ventricle \< 30%, malignant arrhythmias, severe heart valve disease * Personal history of malignancy, personal or family history of medullary thyroid carcinoma * Personal history of pancreatitis or cholelithiasis * Personal history of acute coronary events or hemodynamically significant coronary artery disease * Current treatment with sympathomimetics or sympatholytic * Psychiatric disorders, personal history of …